enzyme). During her illness the antistreptococcal DNAase B became positive, suggesting a recent streptococcal infection. The skin improved but liver function deteriorated; she went into hepatic coma and was transferred to King's College Hospital, but despite hepatic transplantation she died.
These cases followed a similar clinical pattern. In both continuous treatment with minocycline was followed after 32 days (case 1) and 29 days (case 2) by a severe exfoliative rash that became pustular with an inflammatory element showing features of both toxic epidermal necrolysis and erythema multiforme. The rash improved after 10 days (case 1) and 14 days (case 2). The liver function tests were abnormal at 42 days (case 1) and 37 days (case 2). In both they deteriorated but were showing evidence of improvement, in case 1 at 60 days. A curious feature was the positive antistreptococcal DNAase B, the titre of which rose during the early part of the illness in both cases. This test is much more specific for a streptococcal infection than the antistreptolysin 0 titre and appears to reflect true recent infection. There is one previous case report of hepatitis associated with minocycline in a patient with an aspiration pneumonia. In that case the pneumonia, from which cultures grew Staphylococcus aureus and Streptococcus salivarius, had been treated with minocycline and ampicillin. The Committee on Safety of Medicines has received nine reports of hepatic dysfunction associated with minocycline and eight reports of rashes, one of which was described as exfoliative dermatitis.
We believe that there is a case for caution in the use of minocycline for minor skin complaints and would be interested to hear of any other patients with a similar history to our two patients. 
Idiosyncratic dapsone induced manic depression
Drs ANDREW J CARMICHAEL and C J PAUL (Skin Hospital, Birmingham B15 1PR) write: We have recently seen a case of manic depressive psychosis induced by dapsone and unrelated to leprosy.
A 37 year old white woman had suffered recurrent attacks of erythema multiforme for seven years, localised to the skin of the arms. Attacks occurred most months, with the lesions spontaneously settling over two weeks. Investigations for an underlying cause, including lupus erythematosus, gave negative results, and she was otherwise well. A more extensive episode of erythema multiforme affecting the face prompted us to start dapsone 100 mg/day in view of our recent experience of response to this treatment.' Twenty four hours after starting the drug the patient had a two day episode of hypomania, with flight of ideas, pressure of speech, marked hyperactivity, and lack of need for sleep. After three more days she entered a depressive state, becoming withdrawn, low in affect, and tearful, with no change in her life circumstances. She gave no personal or family history of psychiatric problems and was taking no other medication. Her haemoglobin concentration was normal and methaemoglobin was undetected. Dapsone was stopped after 10 days' treatment and within a fortnight her mood had returned to normal. The erythema multiforme cleared after a week's treatment with dapsone but relapsed three weeks after discontinuing treatment.
Dapsone associated "psychosis" has been the subject of controversy.' The debate has been muddied both by imprecise classification of the psychosis and by all but one2 recorded case occurring against a background of leprosy, which may itself be associated with psychotic symptoms.' Some have suggested that "dapsone psychosis" is dose related,' occurs only in those with a background of psychiatric problems,4 and is therefore partly predictable. In view of the strong temporal relation of our patient's symptoms to dapsone treatment and her recovery after its withdrawal we believe that her manic depressive psychosis was a side effect ofdapsone. Rechallenge was not thought to be ethical given the severity of the psychiatric symptoms. This manic-depressive reaction, like the severe agitation in the non-lepromatous patient described by Fine et al,2 appeared after a small dose of dapsone with no predisposing factors and was therefore unpredictable. 
Breathlessness in patients with
complained of breathlessness on exertion within a month of starting cyproterone acetate. Two were dyspnoeic while undressing. None had wheezed or experienced orthopnoea. Blood gas pressures and pH are also shown in the table. All showed a normal arterial oxygen pressure, a low carbon dioxide pressure, and a high normal pH with a low bicarbonate concentration, which indicated a chronic or compensated respiratory alkalosis. Repeat studies in two of the patients after three and 13 months, while they were still taking cyproterone acetate, showed the persistence of the chronic respiratory alkalosis. Two men stopped cyproterone (table) and noticed an improvement in breathlessness within a few days. Further studies in one man 16 months after he stopped treatment showed that his hyperventilation had ceased and his arterial carbon dioxide pressure and pH were both normal.
Progesterone and progestogens stimulate ventilation and increase the sensitivity of the respiratory centre to carbon dioxide.' One of the causes of breathlessness during pregnancy is hyperventilation caused by the increased progesterone secretion,2 and medroxyprogesterone has been used as a respiratory stimulant in patients with chronic ventilatory failure.3 Cyproterone acetate acts as an antiandrogen by blocking androgen receptors. It also has progestogenic activity, exerting a negative feedback effect on the hypothalamic receptors, thus diminishing gonadotrophin release. 4 Our patients attributed their pulmonary symptoms to the cyproterone since all noticed breathlessness soon after treatment started. None had sufficient underlying lung disease or sufficiently abnormal pulmonary function to account for their dyspnoea. All had normal arterial oxygen pressures and evidence of a chronic or compensated respiratory alkalosis consistent with a chronic stimulus to hyperventilation. In one man the dyspnoea and acid base abnormality resolved after the cyproterone was stopped. In another, who declined further tests, breathlessness improved after cyproterone was stopped. In the absence of any other cause of breathlessness we postulate that it was due to the progestogenic effects of cyproterone acetate increasing ventilation in patients with a pre-existing mild to moderate degree of abnormal pulmonary function.
